|
1
|
Coon JT, Hoyle M, Green C, Liu Z, Welch K,
Moxham T and Stein K: Bevacizumab, sorafenib tosylate, sunitinib
and temsirolimus for renal cell carcinoma: A systematic review and
economic evaluation. Health Technol Assess. 14:1–184. 2010.
|
|
2
|
Schachter LR, Cookson MS, Chang SS, Smith
JA Jr, Dietrich MS, Jayaram G and Herrell SD: Second prize:
Frequency of benign renal cortical tumors and histologic subtypes
based on size in a contemporary series: What to tell our patients.
J Endourol. 21:819–823. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhat S: Bhat. Indian J Urol. 26:167–176.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thyavihally YB, Mahantshetty U,
Chamarajanagar RS, Raibhattanavar SG and Tongaonkar HB: Management
of renal cell carcinoma with solitary metastasis. World J Surg
Oncol. 3:482005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyata Y, Koga S, Kanda S, Nishikido M,
Hayashi T and Kanetake H: Expression of cyclooxygenase-2 in renal
cell carcinoma: Correlation with tumor cell proliferation,
apoptosis, angiogenesis, expression of matrix metalloproteinase-2,
and survival. Clin Cancer Res. 9:1741–1749. 2003.PubMed/NCBI
|
|
6
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bruno JJ II, Snyder ME, Motzer RJ and
Russo P: Renal cell carcinoma local recurrences: Impact of surgical
treatment and concomitant metastasis on survival. BJU Int.
97:933–938. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spano D and Zollo M: Tumor
microenvironment: A main actor in the metastasis process. Clin Exp
Metastasis. 29:381–395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X: Wang. In Silico Biol. 11:1–10.
2011–2012.
|
|
11
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanaka T, Torigoe T, Hirohashi Y, Sato E,
Honma I, Kitamura H, Masumori N, Tsukamoto T and Sato N:
Hypoxia-inducible factor (HIF)-independent expression mechanism and
novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
J Cancer Res Clin Oncol. 140:503–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gati A, Da Rocha S, Guerra N, Escudier B,
Moretta A, Chouaib S, Angevin E and Caignard A: Analysis of the
natural killer mediated immune response in metastatic renal cell
carcinoma patients. Int J Cancer. 109:393–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamburger AW, White CP and Dunn FE:
Secretion of transforming growth factors by primary human tumour
cells. Br J Cancer. 51:9–14. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakayama GR, Caton MC, Nova MP and
Parandoosh Z: Assessment of the Alamar Blue assay for cellular
growth and viability in vitro. J Immunol Methods. 204:205–208.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boos DD and Stefanski LA: P-Value
precision and reproducibility. Am Stat. 65:213–221. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khan MI, Dębski KJ, Dabrowski M, Czarnecka
AM and Szczylik C: Gene set enrichment analysis and ingenuity
pathway analysis of metastatic clear cell renal cell carcinoma cell
line. Am J Physiol Renal Physiol. 311:F424–F436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khan MI, Czarnecka AM, Lewicki S,
Helbrecht I, Brodaczewska K, Koch I, Zdanowski R, Król M and
Szczylik C: Comparative gene expression profiling of primary and
metastatic renal cell carcinoma stem cell-like cancer cells. PLoS
One. 11:e01657182016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dresen IM, Hüsing J, Kruse E, Boes T and
Jöckel KH: Software packages for quantitative microarray-based gene
expression analysis. Curr Pharm Biotechnol. 4:417–437. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Savli H, Szendröi A, Romics I and Nagy B:
Gene network and canonical pathway analysis in prostate cancer: A
microarray study. Exp Mol Med. 40:176–185. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krämer A, Green J, Pollard J Jr and
Tugendreich S: Causal analysis approaches in ingenuity pathway
analysis. Bioinformatics. 30:523–530. 2014. View Article : Google Scholar :
|
|
22
|
Harris MA, Clark J, Ireland A, Lomax J,
Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C,
et al: Gene Ontology Consortium: The Gene Ontology (GO) database
and informatics resource. Nucleic Acids Res. 32:D258–D261. 2004.
View Article : Google Scholar
|
|
23
|
Balakrishnan R, Harris MA, Huntley R, Van
Auken K and Cherry JM: A guide to best practices for Gene Ontology
(GO) manual annotation. Database (Oxford). 2013.bat0542013.
|
|
24
|
Kutmon M, Riutta A, Nunes N, Hanspers K,
Willighagen EL, Bohler A, Mélius J, Waagmeester A, Sinha SR, Miller
R, et al: WikiPathways: Capturing the full diversity of pathway
knowledge. Nucleic Acids Res. 44(D1): D488–D494. 2016. View Article : Google Scholar :
|
|
25
|
Network TCGAR, Cancer Genome Atlas and
Research Network: Comprehensive molecular characterization of clear
cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar
|
|
26
|
Cancer Genome Atlas Research Network;
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis
C, Wheeler DA, Murray BA, et al: Comprehensive molecular
characterization of papillary renal-cell carcinoma. N Engl J Med.
374:135–145. 2016. View Article : Google Scholar
|
|
27
|
Kinnaird A and Michelakis ED: Metabolic
modulation of cancer: A new frontier with great translational
potential. J Mol Med (Berl). 93:127–142. 2015. View Article : Google Scholar
|
|
28
|
Khan MI, Sobocińska AA, Czarnecka AM, Król
M, Botta B and Szczylik C: The therapeutic aspects of the
endocannabinoid system (ECS) for cancer and their development: From
nature to laboratory. Curr Pharm Des. 22:1756–1766. 2016.
View Article : Google Scholar
|
|
29
|
Thoppil RJ and Bishayee A: Terpenoids as
potential chemopreventive and therapeutic agents in liver cancer.
World J Hepatol. 3:228–249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alizadeh J, Zeki AA, Mirzaei N, Tewary S,
Rezaei Moghadam A, Glogowska A, Nagakannan P, Eftekharpour E,
Wiechec E, Gordon JW, et al: Mevalonate cascade inhibition by
simvastatin induces the intrinsic apoptosis pathway via depletion
of isoprenoids in tumor cells. Sci Rep. 7:448412017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Damen JE, Liu L, Rosten P, Humphries RK,
Jefferson AB, Majerus PW and Krystal G: The 145-kDa protein induced
to associate with Shc by multiple cytokines is an inositol
tetraphosphate and phosphatidylinositol 3,4,5-triphosphate
5-phosphatase. Proc Natl Acad Sci USA. 93:1689–1693. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB, et al: The I3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun Z, Cao B and Wu J: Protease-activated
receptor 2 enhances renal cell carcinoma cell invasion and
migration via PI3K/AKT signaling pathway. Exp Mol Pathol.
98:382–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang M and Huang CZ: Mitogen-activated
protein kinase signaling pathway and invasion and metastasis of
gastric cancer. World J Gastroenterol. 21:11673–11679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ellinger J, Kahl P, Mertens C, Rogenhofer
S, Hauser S, Hartmann W, Bastian PJ, Büttner R, Müller SC and von
Ruecker A: Prognostic relevance of global histone H3 lysine 4
(H3K4) methylation in renal cell carcinoma. Int J Cancer.
127:2360–2366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Szatmári T and Dobra K: The role of
syndecan-1 in cellular signaling and its effects on heparan sulfate
biosynthesis in mesenchymal tumors. Front Oncol. 3:3102013.
View Article : Google Scholar
|
|
37
|
Kamińska K, Szczylik C, Bielecka ZF,
Bartnik E, Porta C, Lian F and Czarnecka AM: The role of the
cell-cell interactions in cancer progression. J Cell Mol Med.
19:283–296. 2015. View Article : Google Scholar
|
|
38
|
Myszczyszyn A, Czarnecka AM, Matak D,
Szymanski L, Lian F, Kornakiewicz A, Bartnik E, Kukwa W, Kieda C
and Szczylik C: The role of hypoxia and cancer stem cells in renal
cell carcinoma pathogenesis. Stem Cell Rev. 11:919–943. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Woodard J, Joshi S, Viollet B, Hay N and
Platanias LC: AMPK as a therapeutic target in renal cell carcinoma.
Cancer Biol Ther. 10:1168–1177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tong WH, Sourbier C, Kovtunovych G, Jeong
SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, et
al: The glycolytic shift in fumarate-hydratase-deficient kidney
cancer lowers AMPK levels, increases anabolic propensities and
lowers cellular iron levels. Cancer Cell. 20:315–327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li S, Priceman SJ, Xin H, Zhang W, Deng J,
Liu Y, Huang J, Zhu W, Chen M, Hu W, et al: Icaritin inhibits
JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One.
8:e816572013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu
YH, Sung JS, Cha TL and Sun GH: Tumor-derived tumor necrosis
factor-alpha promotes progression and epithelial-mesenchymal
transition in renal cell carcinoma cells. Cancer Sci. 99:905–913.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sievers E, Dreimuller P, Haferkamp A,
Schmidt-Wolf IG, Buchler MW, Schmidt J and Marten A:
Characterization of primary renal carcinoma cultures. Urol Int.
79:235–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shariat SF, Andrews B, Kattan MW, Kim J,
Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its
soluble receptor are associated with prostate cancer progression
and metastasis. Urology. 58:1008–1015. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Müllberg J, Schooltink H, Stoyan T,
Günther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC and
Rose-John S: The soluble interleukin-6 receptor is generated by
shedding. Eur J Immunol. 23:473–480. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Müllberg J, Oberthür W, Lottspeich F, Mehl
E, Dittrich E, Graeve L, Heinrich PC and Rose-John S: The soluble
human IL-6 receptor. Mutational characterization of the proteolytic
cleavage site. J Immunol. 152:4958–4968. 1994.PubMed/NCBI
|
|
47
|
Kamińska K, Czarnecka AM, Escudier B, Lian
F and Szczylik C: Interleukin-6 as an emerging regulator of renal
cell cancer. Urol Oncol. 33:476–485. 2015. View Article : Google Scholar
|
|
48
|
Masson D, Rioux-Leclercq N, Fergelot P,
Jouan F, Mottier S, Théoleyre S, Bach-Ngohou K, Patard JJ and Denis
MG: Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Eur J Cancer. 46:1430–1437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kishimoto T: Kishimoto. Int Immunol.
22:347–352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mihara M, Hashizume M, Yoshida H, Suzuki M
and Shiina M: IL-6/IL-6 receptor system and its role in
physiological and pathological conditions. Clin Sci (Lond).
122:143–159. 2012. View Article : Google Scholar
|
|
51
|
Matsumoto M, Tsujino T, Lee-Kawabata M,
Naito Y, Sakoda T, Ohyanagi M and Masuyama T: Serum interleukin-6
and C-reactive protein are markedly elevated in acute decompensated
heart failure patients with left ventricular systolic dysfunction.
Cytokine. 49:264–268. 2010. View Article : Google Scholar
|
|
52
|
Jones SA, Horiuchi S, Topley N, Yamamoto N
and Fuller GM: The soluble interleukin 6 receptor: Mechanisms of
production and implications in disease. FASEB J. 15:43–58. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Giridhar PV, Funk HM, Gallo CA, Porollo A,
Mercer CA, Plas DR and Drew AF: Interleukin-6 receptor enhances
early colonization of the murine omentum by upregulation of a
mannose family receptor, LY75, in ovarian tumor cells. Clin Exp
Metastasis. 28:887–897. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Whiteside TL: Whiteside. Oncogene.
27:5904–5912. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Eguchi D, Ohuchida K, Kozono S, Ikenaga N,
Shindo K, Cui L, Fujiwara K, Akagawa S, Ohtsuka T, Takahata S, et
al: MAL2 expression predicts distant metastasis and short survival
in pancreatic cancer. Surgery. 154:573–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Russo J and Russo IH: The role of the
basal stem cell of the human breast in normal development and
cancer. Adv Exp Med Biol. 720:121–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qin Q, Xu Y, He T, Qin C and Xu J: Normal
and disease-related biological functions of Twist1 and underlying
molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar :
|
|
58
|
Sun M, Song CX, Huang H, Frankenberger CA,
Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al:
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth
and metastasis. Proc Natl Acad Sci USA. 110:9920–9925. 2013.
View Article : Google Scholar : PubMed/NCBI
|
